Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Healthcare Today.
Press releases published on October 20, 2025
CINV Drugs Market to Reach USD 2.49 Bn by 2032 | Key Trends, Pipeline Therapies & Leading Players (2025–2032)
Based on region global market is segmented in to Asia Pacific, North America, Europe, Latin America, and Middle East Africa. WILMINGTON, DE, UNITED STATES, October 20, 2025 /EINPresswire.com/ -- Global CINV Existing and Pipeline Drugs Market, valued at …
mRNA Healing Patches Market to Reach USD 635.3 Million by 2035 as Next-Generation RNA Therapeutics Transform Wound Care
Prominent players in the market are LTS Lohmann Therapie-Systeme, Vaxxas, CeraVx, Vaxess Technologies, Youwe Bio, among others. ROCKVILLE, MD, UNITED STATES, October 20, 2025 /EINPresswire.com/ -- The global mRNA healing patches market is set for …
Dentulu Recognized as Quarterfinalist for the 2025 Digital Health Hub Foundation: Digital Health Awards
LOS ANGELES, CA, UNITED STATES, October 19, 2025 /EINPresswire.com/ -- Dentulu, the pioneering leader in Teledentistry and integrated oral-systemic health, is thrilled to announce its selection as a quarterfinalist for the prestigious 2025 Digital Health …
New Clinic in Kitchener-Waterloo for Weight Loss, TRT, and Metabolic Health
Physician-led clinic expands medical weight loss, TRT, hair loss treatment and fatty liver care in Kitchener-Waterloo-Cambridge-Guelph. KITCHENER, ONTARIO, CANADA, October 20, 2025 /EINPresswire.com/ -- True North Metabolic today announced the expansion …
Healthcare startups move fast, but execution can’t keep up, VenturiMatch turns strategy into growth in minutes
Venturous launches VenturiMatch, an AI-driven project platform connecting healthcare startups with seasoned executives—showcased at HLTH 2025. LAS VEGAS, NV, UNITED STATES, October 19, 2025 /EINPresswire.com/ -- Healthcare startups move fast, but …
True North Metabolic Expands Physician-Led Weight Loss Care Across Kitchener-Waterloo
Medical weight loss and fatty liver services now available to Kitchener-Waterloo with access for Cambridge and Guelph patients. KITCHENER, ONTARIO, CANADA, October 20, 2025 /EINPresswire.com/ -- True North Metabolic announced the regional expansion of …
تعلن داراديا عن ورش عمل على الجثث حول إجراءات الألم باستخدام C-Arm وUSG: بمشاركة 35-40 طبيبًا لكل دفعة و150 طبيبًا سنويً
KOLKATA, WEST BENGAL, INDIA, October 20, 2025 /EINPresswire.com/ -- أعلنت داراديا: عيادة الألم عن استمرار سلسلة ورش العمل الكادافيرية للتدخلات العلاجية للألم المعتمدة على التصوير بالتنظير التألقي C-Arm والموجات فوق الصوتية USG، وفق جدول منتظم كل ثلاثة …
Dulaglutide Market to Expand at a 7.5% CAGR by 2029, Reaching US $5.97 Billion
The Business Research Company's Dulaglutide Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, October 20, 2025 /EINPresswire.com/ -- "Get 20% Off All Global Market Reports With Code …
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
– Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to fulvestrant – NEW HAVEN, Conn., Oct. …
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust efficacy and safety Combination arm with pembrolizumab (Keytruda®) in Australia near to completion by end 2025 …
Medela AG Introduces the New Motion InBra™ Wearable Breast Pump – Where Dependable Performance Meets Everyday Comfort
Baar, Switzerland, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medela, the brand trusted by millions of moms worldwide and the #1 brand in hospitals [1], today announced the launch of its newest innovation: the Motion InBra™, a highly efficient wearable breast pump …
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed …
Communiqué de presse : ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines (...)
ESMO : les données de l’essai de phase 2 soulignent le potentiel thérapeutique prometteur d’AlphaMedix™ en tant que pionnier de la nouvelle classe des alphathérapies ciblées contre les tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP) Les …
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical …
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma …
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed …
Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard
Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard Par rapport aux vaccins antigrippaux à dose standard, Efluelda/Fluzone High-Dose a démontré …